review of glp 1 IUPHAR – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target Multifaceted Roles of GLP-1 and

Inhibition of PI3K/Akt activity alleviated NTG-induced mechanical hypersensitivity To evaluate whether PI3K/ Akt is involved in NTG-induced pain hypersensitivity, we i.p

doi: 10.1152/ajpendo.00409.2011 54 MinokoshiYAlquierTFurukawaNKimYBLeeAXueBet al

Lilly's currently approved injection, Zepbound, and Novo Nordisk's Wegovy have shown weight loss of roughly 15% to 20% in different trials, according to Reuters, while Lilly's oral obesity pill, Foundayo, has delivered about 11% weight loss

Some patients have genetic variants that make them more sensitive to GLP-1's appetite-suppressing effects, while others may benefit from slightly higher calorie targets to preserve lean mass